Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/62410
Title: One year study of Implanon on the adverse events and discontinuation
Authors: Somsak Chaovisitsaree
Wirawit Piyamongkol
Saipin Pongsatha
Nuntana Morakote
Supranee Noium
Nuchanart Soonthornlimsiri
Authors: Somsak Chaovisitsaree
Wirawit Piyamongkol
Saipin Pongsatha
Nuntana Morakote
Supranee Noium
Nuchanart Soonthornlimsiri
Keywords: Medicine
Issue Date: 1-Mar-2005
Abstract: Objective: To determine adverse events and discontinuation of Implanon in healthy Thai women between 16 and 45 years of age. Design: Prospective descriptive study. Setting: Family Planning Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University. Subjects: Ninety-two female volunteers with eligible criteria, no contraindication for hormonal contraceptive and wished to have long term contraception were recruited. Main outcome measures: Determination of adverse events was done three months after Implanon insertion. Discontinuation of Implanon use was reviewed during the study period of one year. Results: Amenorrhea (40.2%) and infrequent bleeding (39.1%) were the most menstrual adverse events. While most non-menstrual adverse events were headache/dizziness (27.2%) and lower abdominal pain (23.9%). Severe non-menstrual side effect was rare (1-2%). Seven subjects (7.6%) discontinued using Implanon during the one year period of study. Conclusion: Implanon demonstrated a high continue rate at the first year of insertion. It produced similar adverse events like other progestin-only contraceptives. Counseling before insertion is important for increased client satisfaction and a higher continuation rate.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=20344390013&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/62410
ISSN: 01252208
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.